Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology

Executive Summary

With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.

Advertisement

Related Content

Roche/AbbVie Move Beyond GDC-0199 Toxicity Issue To Show Results In Tough-To-Treat CLL
Roche Has Hopes Of Accelerating Hematology Programs With Surrogate Endpoint
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line
Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use
Final Perjeta Overall Survival Data Delayed By Its Efficacy
Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Bristol’s New Anti-PD-1 Immunotherapy An ASCO High Point
Curis Set For Transformative Year With Erivedge Skin Cancer Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel